Health Condition 1: C819- Hodgkin lymphoma, unspecified Health Condition 2: C500- Malignant neoplasm of nipple and areola Health Condition 3: C649- Malignant neoplasm of unspecifiedkidney, except renal pelvis
Conditions
Interventions
Intervention1: NIL: NIL
Control Intervention1: NIL: NIL
Sponsors
The Netherlands Cancer Institute
Eligibility
Inclusion criteria
Inclusion criteria: INCLUSION CRITERIA: 1. Patients of either gender and aged >= 18 years 2. Mentally fit to complete a questionnaire 3. Able to understand the language of the questionnaire 4. Patient is willing to give written informed consent 5. Confirmed cancer diagnosis with one of 11 tumor types 6. Patient has only one cancer diagnosis 7. At least 12 months post-primary treatment with curative intent (exception glioma and maintenance therapies eg tamoxifen) 8. No evidence of active disease (exception glioma grade I, II, and III)
Exclusion criteria
Exclusion criteria: EXCLUSION CRITERIA: 1. Patients not willing to provide written signed informed consent for study participation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1) Development of a health-related quality of life questionnaire (HRQOL) in cancer survivors.Timepoint: Post 1 year after the end of curative treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) To determine the minimum time when the survivorship long-term health-related quality of life (HRQOL) questionnaire should be used in cancer survivors after they have completed the curative treatment.Timepoint: 1-10 years post the end of curative treatment | — |
Countries
Belgium, Croatia, India, Spain, United Kingdom
Contacts
Public ContactDr Manjunath Nookala Krishnamurthy
Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)
Outcome results
None listed